Michael Huang

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA.

Elixiron Immunotherapeutics, Inc. is a privately-held biotechnology company based in Taipei, Taiwan. The Taiwanese company is focused on developing next-generation immunotherapies for unmet needs in immunological and degenerative diseases, as well as cancer. The company's drug discovery engine has allowed them to advance two clinical stage assets and several early-stage candidates. The CEO of the company is Hung-Kai Chen.

Elixiron Immunotherapeutics, Inc. is a privately-held biotechnology company based in Taipei, Taiwan. The Taiwanese company is focused on developing next-generation immunotherapies for unmet needs in immunological and degenerative diseases, as well as cancer. The company's drug discovery engine has allowed them to advance two clinical stage assets and several early-stage candidates. The CEO of the company is Hung-Kai Chen.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA.

Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA.

Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA.

Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA.

Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA.

Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA.

Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA.

Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA.

Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA.

Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA.

Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA.